Skip to main content
Erschienen in: Journal of Endocrinological Investigation 6/2021

01.06.2021 | Review

Efficacy of parathyroidectomy compared with active surveillance in patients with mild asymptomatic primary hyperparathyroidism: a systematic review and meta-analysis of randomized-controlled studies

verfasst von: P. Anagnostis, K. Vaitsi, S. Veneti, V. Potoupni, E. Kenanidis, E. Tsiridis, T. S. Papavramidis, D. G. Goulis

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

Parathyroidectomy (PTx) has an established benefit in patients with symptomatic primary hyperparathyroidism (PHPT). However, its efficacy in mild asymptomatic PHPT has not been proven. This study aimed to systematically review and meta-analyze the best available evidence from randomized-controlled trials comparing the efficacy of PTx over conservative management (non-PTx) on skeletal outcomes [fractures and bone mineral density (BMD)], nephrolithiasis risk and quality of life (QoL) in patients with mild asymptomatic PHPT.

Methods

A comprehensive literature search was conducted in PubMed, Scopus and Cochrane databases, from conception to February 23, 2020. Data were extracted from the studies that fulfilled the eligibility criteria and were synthesized quantitatively (fixed or random effects model) as relative risks and percentage mean differences (MD) with 95% confidence intervals (CI). I2 index was employed for heterogeneity.

Results

Four studies were included in the meta-analysis. There was no difference in fracture risk between PTx and active surveillance. The PTx group demonstrated higher BMD [MD 3.55% (95% CI 1.81, 5.29) in lumbar spine and 3.44% (95% CI 1.39, 5.49) in total hip, without difference in femoral neck and forearm] and lower calcium concentrations (MD − 13.26%, 95% CI − 7.10, − 19.43) compared with the non-PTx group. No difference was observed between groups regarding nephrolithiasis or QoL indices, except for general health (higher in PTx group).

Conclusions

In patients with mild asymptomatic PHPT, PTx increases BMD and reduces serum calcium concentrations. However, its superiority over active surveillance in terms of fracture risk, nephrolithiasis and QoL cannot be supported by current data.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Walker MD, Silverberg SJ (2018) Primary hyperparathyroidism. Nat Rev Endocrinol 14:115–125CrossRef Walker MD, Silverberg SJ (2018) Primary hyperparathyroidism. Nat Rev Endocrinol 14:115–125CrossRef
2.
Zurück zum Zitat Clarke BL (2013) Epidemiology of primary hyperparathyroidism. J Clin Densitom 16:8–13CrossRef Clarke BL (2013) Epidemiology of primary hyperparathyroidism. J Clin Densitom 16:8–13CrossRef
3.
Zurück zum Zitat Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561–3569CrossRef Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561–3569CrossRef
4.
Zurück zum Zitat Wilhelm SM, Wang TS, Ruan DT et al (2016) The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151:959–968CrossRef Wilhelm SM, Wang TS, Ruan DT et al (2016) The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151:959–968CrossRef
5.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341CrossRef
6.
Zurück zum Zitat Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415–5422CrossRef Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415–5422CrossRef
7.
Zurück zum Zitat Ambrogini E, Cetani F, Cianferotti L et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114–3121CrossRef Ambrogini E, Cetani F, Cianferotti L et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114–3121CrossRef
8.
Zurück zum Zitat Bollerslev J, Jansson S, Mollerup CL et al (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687–1692CrossRef Bollerslev J, Jansson S, Mollerup CL et al (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687–1692CrossRef
9.
Zurück zum Zitat Perrier ND, Balachandran D, Wefel JS et al (2009) Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery 146:1116–1122CrossRef Perrier ND, Balachandran D, Wefel JS et al (2009) Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery 146:1116–1122CrossRef
10.
Zurück zum Zitat Lundstam K, Heck A, Mollerup C et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100:1359–1367CrossRef Lundstam K, Heck A, Mollerup C et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100:1359–1367CrossRef
11.
Zurück zum Zitat Lundstam K, Heck A, Godang K et al (2017) Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J Bone Miner Res 32:1907–1914CrossRef Lundstam K, Heck A, Godang K et al (2017) Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J Bone Miner Res 32:1907–1914CrossRef
12.
Zurück zum Zitat Horiuchi T, Onouchi T, Inoue J, Shionoiri A, Hosoi T, Orimo H (2002) A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology 48:103–108CrossRef Horiuchi T, Onouchi T, Inoue J, Shionoiri A, Hosoi T, Orimo H (2002) A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology 48:103–108CrossRef
13.
Zurück zum Zitat Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360–368CrossRef Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360–368CrossRef
14.
Zurück zum Zitat Leere JS, Karmisholt J, Robaczyk M, Vestergaard P (2017) Contemporary medical management of primary hyperparathyroidism: a systematic review. Front Endocrinol (Lausanne) 8:79CrossRef Leere JS, Karmisholt J, Robaczyk M, Vestergaard P (2017) Contemporary medical management of primary hyperparathyroidism: a systematic review. Front Endocrinol (Lausanne) 8:79CrossRef
15.
Zurück zum Zitat Tournis S, Fakidari E, Dontas I et al (2014) Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J Bone Miner Metab 32:151–158CrossRef Tournis S, Fakidari E, Dontas I et al (2014) Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J Bone Miner Metab 32:151–158CrossRef
16.
Zurück zum Zitat Yeh MW, Zhou H, Adams AL, Ituarte PH, Li N, Liu IL, Haigh PI (2016) The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 164:715–723CrossRef Yeh MW, Zhou H, Adams AL, Ituarte PH, Li N, Liu IL, Haigh PI (2016) The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 164:715–723CrossRef
17.
Zurück zum Zitat Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M, Falchetti A, Chiodini I (2018) Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 66:518–524CrossRef Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M, Falchetti A, Chiodini I (2018) Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 66:518–524CrossRef
18.
Zurück zum Zitat Pawlowska M, Cusano NE (2015) An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes 22:413–421CrossRef Pawlowska M, Cusano NE (2015) An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes 22:413–421CrossRef
19.
Zurück zum Zitat Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R (2020) Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab 105(4):e1171–e1186CrossRef Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R (2020) Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab 105(4):e1171–e1186CrossRef
20.
Zurück zum Zitat Palermo A, Naciu AM, Tabacco G et al (2020) Clinical, biochemical and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 105:dgaa174CrossRef Palermo A, Naciu AM, Tabacco G et al (2020) Clinical, biochemical and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 105:dgaa174CrossRef
21.
Zurück zum Zitat Sankaran S, Gamble G, Bolland M, Reid IR, Grey A (2010) Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 95:1653–1662CrossRef Sankaran S, Gamble G, Bolland M, Reid IR, Grey A (2010) Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 95:1653–1662CrossRef
22.
Zurück zum Zitat Singh Ospina N, Maraka S, Rodriguez-Gutierrez R et al (2016) Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis. Osteoporos Int 27:3395–3407CrossRef Singh Ospina N, Maraka S, Rodriguez-Gutierrez R et al (2016) Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis. Osteoporos Int 27:3395–3407CrossRef
23.
Zurück zum Zitat Zhang L, Liu X, Li H (2018) Long-term skeletal outcomes of primary hyperparathyroidism patients after treatment with parathyroidectomy: a systematic review and meta-analysis. Horm Metab Res 50:242–249CrossRef Zhang L, Liu X, Li H (2018) Long-term skeletal outcomes of primary hyperparathyroidism patients after treatment with parathyroidectomy: a systematic review and meta-analysis. Horm Metab Res 50:242–249CrossRef
24.
Zurück zum Zitat VanderWalde LH, Liu IL, O’Connell TX, Haigh PI (2006) The effect of parathyroidectomy on bone fracture risk in patients with primary hyperparathyroidism. Arch Surg 141:885–889 ((discussion 889-891))CrossRef VanderWalde LH, Liu IL, O’Connell TX, Haigh PI (2006) The effect of parathyroidectomy on bone fracture risk in patients with primary hyperparathyroidism. Arch Surg 141:885–889 ((discussion 889-891))CrossRef
25.
Zurück zum Zitat VanderWalde LH, Liu IL, Haigh PI (2009) Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism. World J Surg 33:406–411CrossRef VanderWalde LH, Liu IL, Haigh PI (2009) Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism. World J Surg 33:406–411CrossRef
26.
Zurück zum Zitat Fang WL, Tseng LM, Chen JY, Chiou SY, Chou YH, Wu CW, Lee CH (2008) The management of high-risk patients with primary hyperparathyroidism—minimally invasive parathyroidectomy vs. medical treatment. Clin Endocrinol (Oxf) 68:520–528CrossRef Fang WL, Tseng LM, Chen JY, Chiou SY, Chou YH, Wu CW, Lee CH (2008) The management of high-risk patients with primary hyperparathyroidism—minimally invasive parathyroidectomy vs. medical treatment. Clin Endocrinol (Oxf) 68:520–528CrossRef
27.
Zurück zum Zitat Vestergaard P, Mosekilde L (2003) Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 327:530–534CrossRef Vestergaard P, Mosekilde L (2003) Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 327:530–534CrossRef
28.
Zurück zum Zitat Sharma J, Itum DS, Moss L, Li C, Weber C (2014) Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism. World J Surg 38:1268–1273CrossRef Sharma J, Itum DS, Moss L, Li C, Weber C (2014) Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism. World J Surg 38:1268–1273CrossRef
29.
Zurück zum Zitat Castellano E, Attanasio R, Boriano A et al (2017) Sex difference in the clinical presentation of primary hyperparathyroidism: influence of menopausal status. J Clin Endocrinol Metab 102:4148–4152CrossRef Castellano E, Attanasio R, Boriano A et al (2017) Sex difference in the clinical presentation of primary hyperparathyroidism: influence of menopausal status. J Clin Endocrinol Metab 102:4148–4152CrossRef
30.
Zurück zum Zitat Madeo B, Kara E, Cioni K et al (2017) Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR Plus 2:109–117CrossRef Madeo B, Kara E, Cioni K et al (2017) Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR Plus 2:109–117CrossRef
Metadaten
Titel
Efficacy of parathyroidectomy compared with active surveillance in patients with mild asymptomatic primary hyperparathyroidism: a systematic review and meta-analysis of randomized-controlled studies
verfasst von
P. Anagnostis
K. Vaitsi
S. Veneti
V. Potoupni
E. Kenanidis
E. Tsiridis
T. S. Papavramidis
D. G. Goulis
Publikationsdatum
01.06.2021
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 6/2021
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-020-01447-7

Weitere Artikel der Ausgabe 6/2021

Journal of Endocrinological Investigation 6/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.